Literature DB >> 12653672

Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.

S Taucher1, M Rudas, M Gnant, K Thomanek, P Dubsky, S Roka, T Bachleitner, D Kandioler, C Wenzel, G Steger, M Mittlböck, R Jakesz.   

Abstract

The objective of this analysis was to determine the accuracy of steroid receptor measurement in large core needle biopsies compared with surgically removed specimens and the influence of preoperative chemotherapy on hormone receptor status. We consecutively performed 722 large core needle biopsies in palpable lesions of the breast. The diagnosis of breast cancer was confirmed upon biopsy in 450 patients; 236 women underwent immediate surgery, and 214 patients received preoperative chemotherapy. We assessed estrogen (ER) and progesterone receptor (PR) in biopsy tissue and surgically removed specimens and calculated accuracy, sensitivity, specificity, the weighted kappa value and Spearman's rank correlation. The modulation of steroid receptor status in preoperatively treated patients was tested by Cochran-Mantel-Haenszel statistics. The accuracy of ER evaluation in the biopsy material of patients without intervening chemotherapy was 91%, sensitivity and specificity were 94% and 80% respectively. Accuracy, sensitivity and specificity were 86% in patients treated preoperatively. In terms of PR assessment, we obtained slightly inferior results: accuracy, sensitivity and specificity were 80%, 73% and 85% respectively in patients without preoperative treatment, and 79%, 48% and 92% respectively in patients undergoing preoperative therapy. Following preoperative chemotherapy, patients showed a significant increase in ER-negative (P=0.02) and PR-negative (P=0.0005) measurements. We have concluded from our results that ER and PR receptor measurement in core needle biopsy is a reliable basis in clinical practice for selecting patients for neoadjuvant endocrine treatment. Preoperative cytotoxic chemotherapy induced a significant extent of variation in the steroid receptor expression of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12653672     DOI: 10.1677/erc.0.0100091

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  21 in total

Review 1.  The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.

Authors:  Zsolt Hodi; Jayeta Chakrabarti; Andrew H S Lee; John E Ronan; Christopher W Elston; Kwok Leung Cheung; John F R Robertson; Ian O Ellis
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

2.  Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.

Authors:  Qi-Xing Tan; Qing-Hong Qin; Wei-Ping Yang; Bin Lian; Chang-Yuan Wei
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.

Authors:  William T Barry; Dawn N Kernagis; Holly K Dressman; Ryan J Griffis; J'vonne D Hunter; John A Olson; Jeff R Marks; Geoffrey S Ginsburg; Paul K Marcom; Joseph R Nevins; Joseph Geradts; Michael B Datto
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.

Authors:  Guangchao Jin; Yu Han; Cun Liu; Liansheng Chen; Butong Ding; Shijin Xuan; Xianqiang Liu; Guohui Ma; Jun Gao; Xingsong Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

5.  HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.

Authors:  Norbert Arens; Uwe Bleyl; Ralf Hildenbrand
Journal:  Virchows Arch       Date:  2005-04-19       Impact factor: 4.064

6.  Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.

Authors:  J Xu; C Ni; C Ma; L Zhang; X Jing; C Li; Y Liu; X Qu
Journal:  Clin Transl Oncol       Date:  2017-02-28       Impact factor: 3.405

7.  Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.

Authors:  Pedro Sánchez-Rovira; Antonio Antón; Agustí Barnadas; Amalia Velasco; María Lomas; María Rodríguez-Pinilla; José Luis Ramírez; César Ramírez; María José Ríos; Eva Castellá; Carmen García-Andrade; Belén San Antonio; Eva Carrasco; José Luis Palacios
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

8.  Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.

Authors:  T Hirata; C Shimizu; K Yonemori; A Hirakawa; T Kouno; K Tamura; M Ando; N Katsumata; Y Fujiwara
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

9.  State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.

Authors:  Arnd Honig; Lorenz Rieger; Marc Sutterlin; Diethelm Wallwiener; Johannes Dietl; Erich-Franz Solomayer
Journal:  Ger Med Sci       Date:  2005-09-13

10.  Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.

Authors:  Ou Huang; Canming Chen; Jiayi Wu; Shujie Chen; Xiaosong Chen; Guangyu Liu; Zhen Hu; Jingsong Lu; Jiong Wu; Zhimin Shao; Zhenzhou Shen; Kunwei Shen
Journal:  BMC Cancer       Date:  2009-10-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.